May 28, 2025
Regeneron Pharmaceuticals Inc. on Wednesday pressed a Massachusetts federal judge to ready a long-running False Claims Act suit for a jury and reject the government's second bid for a pretrial win under a different legal theory following a First Circuit setback.
December 20, 2023
A False Claims Act case against Regeneron Pharmaceuticals Inc. will freeze completely while the government and the company argue the appeal of a crucial legal question, the presiding judge said Wednesday.
November 27, 2023
A Massachusetts federal judge has pressed pause on a False Claims Act case against Regeneron while the First Circuit decides whether his interpretation of the law's causation standard or that of his colleague in the same courthouse is correct.
October 18, 2023
A federal judge overseeing a False Claims Act case against Regeneron Pharmaceuticals Inc. said Wednesday he's leaning toward granting a mid-case appeal for the First Circuit to settle a critical legal question that's led to circuit splits and a divergent ruling involving Teva Pharmaceuticals.
September 28, 2023
A Massachusetts federal judge has ruled that the federal government must prove that alleged kickbacks by biotechnology company Regeneron related to its drug Eylea had a direct connection to false claims, addressing an issue that has prompted a significant circuit split.
June 12, 2023
The U.S. Supreme Court's ruling that faulty yet reasonable compliance views can trigger False Claims Act liability is undermining defense bar positions in wide-ranging contexts, including a new circuit split over FCA cases involving kickbacks, according to the U.S. Department of Justice.
April 24, 2023
Regeneron Pharmaceuticals Inc. can't seek more information about a former prosecutor who helped file an anti-kickback lawsuit against the company, a Massachusetts federal judge has ruled, calling allegations that the attorney downloaded files relating to the case when he left for private practice a "minor" issue.
March 09, 2023
Federal prosecutors in Boston on Wednesday told a judge to use "common sense" and set in stone some elements of their civil False Claims Act case alleging Regeneron Pharmaceuticals Inc. funneled illegal kickbacks to patients through a charitable organization.
February 01, 2023
The U.S. Department of Justice ignored and concealed evidence that hollows out the core of a False Claims Act suit accusing Regeneron Pharmaceuticals of defrauding Medicare by disguising kickbacks as charitable donations, the drugmaker asserted in a sweeping bid to avoid trial in Massachusetts.
January 10, 2022
Regeneron Pharmaceuticals can see U.S Food and Drug Administration documents that the company says could undermine claims it paid illegal kickbacks to doctors who prescribed its eye disease drug, a Boston federal judge said Monday.